AKT1 and hepatocellular carcinoma: Although TIMP1 functions as a matrix metalloproteinase inhibitor capable of restraining MMP-mediated matrix degradation, contemporary studies confirm its capacity to activate PI3K/Akt signaling through CD63 binding, promoting hepatocellular carcinoma stem cell self-renewal.